Azenta Guides FY27 Revenue to $648M-$660M After 5% FY26 Growth

Azenta, Inc. (Nasdaq: AZTA) reported fourth-quarter and full-year fiscal 2026 results on November 10, 2026, with full-year revenue from continuing operations of $622 million, up 5% year over year, and organic growth of 2%. Fourth-quarter revenue reached $167 million, also up 5% reported and 2% organic. The Burlington, Massachusetts-based life-sciences sample management and multiomics company guided fiscal 2027 revenue to $648 million to $660 million, with organic growth of 3% to 5% and adjusted EBITDA margin expansion of 200 to 250 basis points. Adjusted diluted EPS for the quarter was $0.28 versus $0.21 a year earlier.

Context — why Azenta's FY27 guide matters now

Azenta closed fiscal 2026 with what management described as improving momentum in the second half. The comparison base matters: full-year organic growth of 2% trailed reported growth of 5%, with the gap split between a 2-percentage-point contribution from the UK Biocentre acquisition and a 1-point foreign exchange tailwind. Stripping those out, the underlying business grew at roughly half the headline rate, which is the number the FY27 guide has to build on.

The company also completed the divestiture of B Medical Systems on July 1, 2026, and received full repayment of a $35 million vendor loan plus accrued interest on September 3, 2026. B Medical is now reported as discontinued operations. That simplifies the story: continuing operations are the sample management and multiomics franchises, and the balance sheet carries $506 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026.

Interim President and CEO Dr. Martin Madaus framed fiscal 2027 as a year of "consistent execution and accelerating performance," pointing to organic growth, profitability, cash generation and strategic initiatives. The company's own numbers show why execution is the operative word: adjusted EBITDA margin from continuing operations fell to 9.4% for the full year from 11.2%, and to 11.6% in Q4 from 13.0%. Margin recovery, not revenue, is the swing factor in the FY27 plan.

For investors tracking the life-sciences tools complex, Azenta's guide arrives against a backdrop where organic growth of 2% has been the recent reality and management is asking the market to underwrite a step-up to 3%-5%. That is a modest acceleration, but it depends on Multiomics, which the company has explicitly targeted as its next growth engine.

Data — what the numbers show

Segment detail explains where growth is coming from. Sample Management Solutions generated $344 million for the full year, up 6% reported and 2% organic, with Q4 revenue of $94 million, up 9% reported and 4% organic. Multiomics delivered $277 million, up 3% reported and 1% organic, with Q4 flat at $73 million and down 1% organic. Within Multiomics, Next Generation Sequencing and Gene Synthesis grew for the year, offset by lower Sanger Sequencing revenue; in Q4, Sanger and NGS declined while Gene Synthesis grew.

The GAAP picture diverges sharply from the adjusted one. Full-year operating loss from continuing operations was $174.7 million, a negative 28.1% operating margin, versus negative 4.5% in fiscal 2025. That swing reflects a non-cash goodwill impairment charge of $149 million booked in operating expenses, which rose 51% to $450 million. Diluted EPS from continuing operations was negative $3.50 versus positive $0.53 a year earlier; total diluted EPS was negative $3.70 versus negative $1.22.

On an adjusted basis, full-year operating income was $9.8 million, a 1.6% margin, down 110 basis points. Adjusted EBITDA was $58.3 million at a 9.4% margin, down 180 basis points. Free cash flow for the year was $27 million, from $58 million in operating cash flow and $30 million of capital expenditures. Q4 free cash flow was $12 million.

Metric	FY26	FY25	Change
Revenue (continuing ops)	$622M	$594M	+5%
Organic growth	2%	—	—
Adjusted EBITDA margin	9.4%	11.2%	-180bps
Adjusted diluted EPS	$0.48	$0.51	-6%

The company repurchased 4.4 million shares for $118.2 million during fiscal 2026 under a $250 million authorization approved December 8, 2025, leaving $131.8 million available.

Analysis — what it means for markets and sectors

The headline tension in these results is that reported revenue growth and GAAP profitability point in opposite directions. A $149 million goodwill impairment is a non-cash charge, so it does not consume the $506 million liquidity pool, but it does signal that prior acquisition carrying values no longer matched expected cash flows. For a company whose thesis rests on portfolio breadth in sample management and multiomics, that is a credibility marker the FY27 guide has to overcome.

Second-order effects run through the life-sciences tools peer group, where organic growth in the low single digits and margin compression have been the sector's recent pattern. Azenta's plan to expand adjusted EBITDA margin by 200 to 250 basis points while absorbing 100 basis points of dilution from the Elegen agreements and SynPlexity acquisition implies roughly 300 to 350 basis points of underlying expansion. That is an aggressive internal target, and it is the single number most exposed to execution risk.

The counter-argument worth weighing: management has already taken cost actions, and Q4 adjusted operating margin expanded 120 basis points year over year to 6.9%, with adjusted gross margin up 50 basis points to 47.2%. The second half did improve. If that trajectory holds, the FY27 margin bridge is less of a leap than the full-year comparison suggests.

Positioning reflects the uncertainty. The stock sits between investors who see a self-help margin story with $506 million of liquidity and a buyback still running, and those who see a business that grew organically 2% with a GAAP loss and a goodwill write-down. The FY27 guide is management's attempt to move the debate from the income statement to the cash flow statement, where free cash flow is expected to improve about 25%.

Outlook — what to watch next

The first checkpoint is the Q1 fiscal 2027 print, guided to organic revenue growth of 3% to 4% and adjusted EBITDA margin expansion of 100 to 150 basis points versus the prior-year quarter. Management will webcast its fiscal 2026 earnings call on November 11, 2026 at 8:30 a.m. Eastern Time, where guidance assumptions and the Elegen and SynPlexity integration plans are likely to draw questions.

Beyond that, the Elegen and SynPlexity deals close the loop on Multiomics strategy. Azenta holds an exclusive license to certain Elegen gene synthesis and cell-free cloning technologies with fixed payments totaling $23.0 million, plus an option exercisable 12 to 18 months after execution to convert to a perpetual license for $25.0 million. Aggregate capital deployment across the agreements is expected to range from roughly $32.0 million to $71.0 million. SynPlexity closed for a $15.0 million base price with up to $10.0 million in contingent consideration tied to a revenue milestone through September 30, 2029.

The company said fiscal 2027 is expected to be primarily a year of integration, scale-up and commercialization for these capabilities, and the high end of the revenue outlook includes their potential contributions. Free cash flow is guided to improve approximately 25%.

Frequently Asked Questions

What does Azenta's FY27 guidance imply for the dividend or buyback?

Azenta's $250 million repurchase authorization, approved December 8, 2025, had $131.8 million remaining as of September 30, 2026, after 4.4 million shares were bought for $118.2 million during fiscal 2026. The company's fiscal 2027 outlook targets roughly 25% free cash flow improvement, which would support continued repurchases, though the report does not commit to a specific pace.